Home > Insider Trading > Filing (0001209191-15-036341)

Filing Details

Accession Number:: 0001209191-15-036341
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2015-04-27 14:40:15
Reporting Period:: 2015-04-14

Filing Date:: 2015-04-27
Accepted Time:: 2015-04-27 14:40:15
Original Submission Date:: 2015-04-14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Carbylan Therapeutics Inc.	CBYL	Pharmaceutical Preparations (2834)	200915291

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397906	Albert Cha	C/O Vivo Capital Llc 575 High Street, Suite 201 Palo Alto CA 94301		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-04-14	2,476,452	$0.00	2,476,452	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	18,140	$0.00	2,494,592	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	387,960	$0.00	2,882,552	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	2,842	$0.00	2,885,394	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	304,438	$0.00	3,189,832	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	2,230	$0.00	3,192,062	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	1,005,136	$5.00	4,197,198	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2015-04-14	7,364	$5.00	4,204,562	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-04-14	2,476,452	$0.00	2,476,452	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-04-14	18,140	$0.00	18,140	$0.00
Common Stock	Convertible Promissory Note	Disposition	2015-04-14	387,960	$0.00	387,960	$0.00
Common Stock	Convertible Promissory Note	Disposition	2015-04-14	2,842	$0.00	2,842	$0.00
Common Stock	Convertible Promissory Note	Disposition	2015-04-14	304,438	$0.00	304,438	$0.00
Common Stock	Convertible Promissory Note	Disposition	2015-04-14	2,230	$0.00	2,230	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one for one basis without payment or further consideration, and has no expiration date.
The reported shares are held directly by Vivo Ventures Fund VI, L.P. ("VIF"). Vivo Ventures VI, LLC ("Vivo LLC") is the general partner of VIF. As such, Vivo LLC may be deemed to be the beneficial owner of the shares held directly by VIF. The managers of Vivo LLC include Frank Kung, Edgar Engleman, and Albert Cha. Accordingly, each Frank Kung, Edgar Engleman and Albert Cha may be deemed to be the beneficial owner of the shares held directly by VIF. Each of Vivo LLC, Frank Kung, Edgar Engleman and Albert Cha disclaims beneficial ownership of the securities held by VIF, except to the extent of such individual's or entity's pecuniary interests in the securities.
The reported shares are held directly by Vivo Ventures VI Affiliates Fund, L.P. ("VIAF"). Vivo Ventures VI, LLC ("Vivo LLC") is the general partner of VIAF. As such, Vivo LLC may be deemed to be the beneficial owner of the shares held directly by VIAF. The managers of Vivo LLC include Frank Kung, Edgar Engleman, and Albert Cha. Accordingly, each Frank Kung, Edgar Engleman and Albert Cha may be deemed to be the beneficial owner of the shares held directly by VIAF. Each of Vivo LLC, Frank Kung, Edgar Engleman and Albert Cha disclaims beneficial ownership of the securities held by VIAF, except to the extent of such individual's or entity's pecuniary interests in the securities.
The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 184 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 41 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
The number of shares in Column 5 represents the aggregate number of shares directly beneficially owned by both VIF and VIAF. Albert Cha is one of the managers of Vivo LLC, the general partner of both VIF and VIAF.